Your session is about to expire
← Back to Search
N/A
PENG Block Versus LP Block for THA Postop Pain
Phase 4
Waitlist Available
Led By Rawad Hamzi, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up hour 24
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial compares two methods for pain relief after hip replacement surgery. One method aims to reduce pain without causing muscle weakness, while the other can lead to muscle weakness. The goal is to find out which method helps patients recover faster.
Eligible Conditions
- Infections
- Postoperative Pain
- Hip Pain
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ hour 24
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~hour 24
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Numeric Rating Scale (NRS) Pain Score
Secondary study objectives
Distance Ambulated
Motor Strength
NRS Pain Score
+1 moreSide effects data
From 2023 Phase 4 trial • 154 Patients • NCT052610091%
Right hip dislocation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Peri-capsular Nerve Group (PENG)
Lumbar Plexus Block (LPB)
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Peri-capsular Nerve Group (PENG)Experimental Treatment1 Intervention
Those subjects assigned to the PENG treatment arm will receive a PENG block using 20mL of 0.2% ropivacaine with 1:400,000 epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
Group II: Lumbar Plexus Block (LPB)Active Control1 Intervention
Those subjects assigned to the LPB treatment arm will receive a stimulation-based LPB dosed with 20cc of 0.2% ropivacaine with 1:400,000 dilution epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Peri-capsular Nerve Group (PENG)
2022
Completed Phase 4
~160
Find a Location
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,397 Previous Clinical Trials
2,459,975 Total Patients Enrolled
13 Trials studying Infections
2,434 Patients Enrolled for Infections
Rawad Hamzi, MDPrincipal InvestigatorWake Forest University Health Sciences
1 Previous Clinical Trials
31 Total Patients Enrolled